Sirtex Medical Limited (ASX:SRX) has reported 34 per cent sales growth for its liver cancer therapy SIR-Spheres microspheres, for the first three months of this year.
The bio-tech company reported 47 per cent growth in the US and 46 per cent in the Asia Pacific region.
Sirtex’s chief says it is the largest increase in the number of doses sold in a quarter in Sirtex’s history.
In the first half of the 2012 financial year, Sirtex Medical reported a net profit of $6.1 million.
